Allergan, an AbbVie Company (NYSE:ABBV), and clinical-stage biotechnology company Molecular Partners (SIX:MOLN) reported on Thursday that that the US Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License Application (BLA) for Abicipar pegol, a novel, investigational DARPin therapy for patients with neovascular (wet) age-related macular degeneration (nAMD).
In the CRL, the FDA indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 ml results in an unfavorable benefit-risk ratio in the treatment of nAMD.
AbbVie intends to meet with the FDA to discuss its comments and determine next steps.
DARPin molecules are derived from naturally occurring binding proteins that consist of repeat sequences with capping structures at each end of the protein. They have three key properties that have made them an important investigational class of binding protein for researchers: high binding affinity, low molecular weight and customizable applications.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007